X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-05-12 | ACON | Aclarion, Inc. | Breidbart Scott | Dir | P - Purchase | $3.18 | +5,664 | 5,664 | New | +$18,012 | ||||||
2026-05-11 | ACON | Aclarion, Inc. | Neal David K | Dir | P - Purchase | $3.10 | +2,500 | 2,502 | >999% | +$7,750 | ||||||
2026-05-11 | CAI | Caris Life Sciences, Inc. | Vacirca Jeff L | Dir | P - Purchase | $16.15 | +31,050 | 49,671 | +167% | +$501,426 | ||||||
2026-05-11 | ACON | Aclarion, Inc. | Ness Brent | CEO | P - Purchase | $3.18 | +6,289 | 6,300 | >999% | +$19,999 | ||||||
| D | 2026-05-07 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $22.15 | -9,836 | 264,727 | -4% | -$217,904 | |||||
2026-05-06 | ACON | Aclarion, Inc. | Wesemann William | Dir | P - Purchase | $3.30 | +1,562 | 1,563 | >999% | +$5,155 | ||||||
2026-05-06 | VCYT | Veracyte, Inc. | McGuire Annie | SVP, GC | S - Sale | $39.03 | -10,204 | 143,708 | -7% | -$398,211 | ||||||
| M | 2026-05-04 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale | $213.05 | -7,708 | 2,382,843 | 0% | -$1,642,211 | |||||
2026-05-04 | CELC | Celcuity Inc. | Dalvey David | Dir | S - Sale | $140.68 | -25,000 | 65,000 | -28% | -$3,517,000 | ||||||
| D | 2026-05-04 | CELC | Celcuity Inc. | Buller Richard E | Dir | S - Sale+OE | $140.47 | -9,000 | 7,789 | -54% | -$1,264,181 | |||||
2026-05-05 | CDNA | Caredx, Inc. | Novack Jeffrey Adam | Secretary, GC | S - Sale | $20.68 | -2,688 | 113,924 | -2% | -$55,581 | ||||||
| M | 2026-05-01 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $208.79 | -795 | 57,496 | -1% | -$165,984 | |||||
2026-05-01 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $206.16 | -107 | 296,216 | 0% | -$22,059 | ||||||
2026-05-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $203.69 | -3,405 | 142,295 | -2% | -$693,560 | ||||||
2026-05-01 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $206.16 | -291 | 187,220 | 0% | -$59,993 | ||||||
2026-05-01 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $206.16 | -902 | 149,867 | -1% | -$185,956 | ||||||
2026-05-01 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $206.16 | -330 | 222,694 | 0% | -$68,033 | ||||||
| M | 2026-04-20 | LUDG | Ludwig Enterprises, Inc. | Hausman Marvin S Md | 10% | S - Sale | $0.02 | -2,000,000 | 37,758,000 | -5% | -$40,000 | |||||
| M | 2026-04-27 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $197.84 | -5,063 | 58,291 | -8% | -$1,001,645 | |||||
2026-04-27 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $204.14 | -5,838 | 150,769 | -4% | -$1,191,775 | ||||||
2026-04-27 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $204.10 | -1,688 | 187,511 | -1% | -$344,517 | ||||||
2026-04-27 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $204.10 | -2,182 | 145,700 | -1% | -$445,341 | ||||||
2026-04-27 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $204.09 | -1,861 | 223,024 | -1% | -$379,811 | ||||||
| M | 2026-04-27 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $197.43 | -3,544 | 296,275 | -1% | -$699,693 | |||||
| D | 2026-04-21 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $25.10 | -4,172 | 268,349 | -2% | -$104,709 | |||||
2026-04-17 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $199.63 | -1,500 | 299,819 | 0% | -$299,441 | ||||||
2026-04-16 | CDNA | Caredx, Inc. | Hanna John Walter Jr | Pres, CEO | S - Sale | $21.12 | -10,282 | 676,475 | -1% | -$217,156 | ||||||
| D | 2026-04-16 | GH | Guardant Health, Inc. | Tariq Musa | Dir | S - Sale+OE | $84.83 | -116 | 8,528 | -1% | -$9,840 | |||||
2026-04-08 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $49.92 | -45,806 | 260,669 | -15% | -$2,286,526 | ||||||
2026-04-08 | GRAL | Grail, Inc. | Ragusa Robert P | CEO | S - Sale | $49.92 | -123,502 | 518,582 | -19% | -$6,164,923 | ||||||
2026-04-08 | GRAL | Grail, Inc. | Ofman Joshua J. | Pres | S - Sale | $49.92 | -61,665 | 371,216 | -14% | -$3,078,169 | ||||||
| D | 2026-04-06 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $25.03 | -9,836 | 271,971 | -3% | -$246,195 | |||||
2026-04-06 | GH | Guardant Health, Inc. | Monroe Terilyn J. | Chief People Officer | S - Sale | $92.68 | -3,832 | 20,990 | -15% | -$355,150 | ||||||
2026-04-01 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $203.31 | -8,400 | 224,885 | -4% | -$1,707,814 | ||||||
2026-04-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $202.30 | -3,000 | 147,882 | -2% | -$606,899 | ||||||
| D | 2026-03-31 | CELC | Celcuity Inc. | Buller Richard E | Dir | S - Sale+OE | $110.27 | -3,000 | 7,789 | -28% | -$330,804 | |||||
2026-03-31 | BNR | Burning Rock Biotech Ltd | Han Yusheng | Dir | P - Purchase | $17.36 | +314,870 | 17,672,676 | +2% | +$5,466,143 | ||||||
| D | 2026-03-26 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $25.55 | -4,172 | 275,593 | -1% | -$106,599 | |||||
2026-03-27 | LH | Labcorp Holdings Inc. | Wilkinson Peter J | SVP, Chief Accounting Officer | S - Sale | $267.05 | -1,633 | 1,852 | -47% | -$436,093 | ||||||
2026-03-27 | LH | Labcorp Holdings Inc. | Meltzer Jonathan C | EVP, Operations | S - Sale | $267.05 | -839 | 3,620 | -19% | -$224,055 | ||||||
2026-03-19 | RDNT | Radnet, Inc. | Sorensen Alma Gregory | Chief Strategy Officer | S - Sale | $62.20 | -15,000 | 1,201,923 | -1% | -$933,014 | ||||||
| M | 2026-03-18 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $198.75 | -4,570 | 301,319 | -1% | -$908,301 | |||||
2026-03-18 | GH | Guardant Health, Inc. | Tariq Musa | Dir | S - Sale | $88.09 | -348 | 8,394 | -4% | -$30,655 | ||||||
| M | 2026-03-17 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $25.91 | -19,300 | 279,215 | -6% | -$500,098 | |||||
2026-03-13 | NTRA | Natera, Inc. | Chapman Rowan E | Dir | S - Sale | $191.38 | -122 | 5,752 | -2% | -$23,348 | ||||||
| D | 2026-03-16 | GH | Guardant Health, Inc. | Bell Michael Brian | CFO | S - Sale+OE | $87.04 | -3,000 | 43,601 | -6% | -$261,111 | |||||
| M | 2026-03-13 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $25.75 | -30,779 | 298,515 | -9% | -$792,410 | |||||
| D | 2026-03-16 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $9.22 | -1,804 | 74,524 | -2% | -$16,633 | |||||
| D | 2026-03-16 | FTRE | Fortrea Holdings Inc. | McConnell Jill G. | CFO | S - Sale+OE | $9.22 | -1,804 | 72,276 | -2% | -$16,633 | |||||
| DM | 2026-03-12 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale+OE | $191.42 | -200,000 | 2,315,772 | -8% | -$38,283,382 | |||||
2026-03-12 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $25.24 | -20,863 | 86,825 | -19% | -$526,582 | ||||||
| DM | 2026-03-11 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $25.67 | -44,125 | 329,294 | -12% | -$1,132,821 | |||||
| M | 2026-03-10 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $1.92 | -25,612 | 738,314 | -3% | -$49,079 | |||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Kearney Paul | Chief Data Officer | S - Sale | $2.04 | -1,396 | 163,961 | -1% | -$2,848 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $2.04 | -1,027 | 114,720 | -1% | -$2,095 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $2.04 | -716 | 76,712 | -1% | -$1,461 | ||||||
2026-03-11 | SERA | Sera Prognostics, Inc. | Boniface John J. | Chief Scientific Officer | S - Sale | $2.04 | -1,517 | 145,842 | -1% | -$3,095 | ||||||
| M | 2026-03-10 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $1.92 | -7,088 | 264,452 | -3% | -$13,610 | |||||
2026-03-10 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $204.13 | -785 | 63,354 | -1% | -$160,244 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $204.13 | -5,623 | 156,607 | -3% | -$1,147,838 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $204.13 | -1,745 | 233,285 | -1% | -$356,212 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $204.13 | -127 | 305,889 | 0% | -$25,925 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $204.13 | -707 | 189,199 | 0% | -$144,322 | ||||||
2026-03-10 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $204.13 | -915 | 150,882 | -1% | -$186,781 | ||||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | Parks Robert | Chief Accounting Officer | S - Sale+OE | $9.07 | -1,927 | 22,389 | -8% | -$17,478 | |||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $9.07 | -4,599 | 72,044 | -6% | -$41,713 | |||||
| D | 2026-03-10 | FTRE | Fortrea Holdings Inc. | McConnell Jill G. | CFO | S - Sale+OE | $9.07 | -5,061 | 69,796 | -7% | -$45,903 | |||||
| D | 2026-03-06 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale+OE | $196.08 | -8,398 | 233,285 | -3% | -$1,646,696 | |||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Kearney Paul | Chief Data Officer | S - Sale | $1.96 | -2,026 | 165,357 | -1% | -$3,971 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $1.96 | -3,119 | 115,747 | -3% | -$6,113 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $1.96 | -3,360 | 77,428 | -4% | -$6,586 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Boniface John J. | Chief Scientific Officer | S - Sale | $1.96 | -3,038 | 147,359 | -2% | -$5,954 | ||||||
2026-03-09 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $1.96 | -674 | 271,540 | 0% | -$1,321 | ||||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $48.96 | -3,147 | 306,475 | -1% | -$154,062 | |||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Ofman Joshua J. | Pres | S - Sale | $48.86 | -3,627 | 432,881 | -1% | -$177,227 | |||||
| M | 2026-03-05 | GRAL | Grail, Inc. | Ragusa Robert P | CEO | S - Sale | $48.48 | -8,441 | 642,084 | -1% | -$409,246 | |||||
| D | 2026-03-06 | GH | Guardant Health, Inc. | Hidalgo Medina Manuel | Dir | S - Sale+OE | $91.54 | -1,300 | 1,193 | -52% | -$118,997 | |||||
2026-03-05 | CSTL | Castle Biosciences Inc | Stokes Frank | CFO | S - Sale | $27.98 | -6,001 | 60,085 | -9% | -$167,908 | ||||||
| D | 2026-03-05 | CSTL | Castle Biosciences Inc | Cole G Bradley | Dir | S - Sale+OE | $28.47 | -7,403 | 19,309 | -28% | -$210,727 | |||||
2026-03-06 | SERA | Sera Prognostics, Inc. | Lawrence Sandra Aj | Dir | S - Sale | $1.95 | -1,560 | 18,033 | -8% | -$3,042 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $206.21 | -5,558 | 71,624 | -7% | -$1,146,115 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale | $206.21 | -3,878 | 43,294 | -8% | -$799,682 | ||||||
2026-03-05 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $206.21 | -2,855 | 15,198 | -16% | -$588,730 | ||||||
2026-03-04 | DGX | Quest Diagnostics Inc | Kuppusamy Karthik | SVP, Clinical Solutions | S - Sale | $204.86 | -2,628 | 15,457 | -15% | -$538,372 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Chambers Rebecca | CFO | S - Sale | $36.14 | -18,341 | 131,196 | -12% | -$662,869 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Stapley Marc | CEO | S - Sale | $35.97 | -45,523 | 357,554 | -11% | -$1,637,594 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | Leite John | Chief Commercial Officer-CLIA | S - Sale | $35.19 | -5,260 | 107,580 | -5% | -$185,083 | ||||||
2026-03-04 | VCYT | Veracyte, Inc. | McGuire Annie | SVP, GC | S - Sale | $35.55 | -6,658 | 94,706 | -7% | -$236,725 | ||||||
| D | 2026-03-04 | GH | Guardant Health, Inc. | Kalia Kumud | CIO | S - Sale+OE | $95.32 | -40,000 | 37,643 | -52% | -$3,812,661 | |||||
| D | 2026-03-03 | CSTL | Castle Biosciences Inc | Stokes Frank | CFO | S - Sale+OE | $27.44 | -7,000 | 66,086 | -10% | -$192,073 | |||||
2026-03-03 | LH | Labcorp Holdings Inc. | Schechter Adam H | Pres, CEO | S - Sale | $279.96 | -8,705 | 80,773 | -10% | -$2,437,047 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $207.73 | -632 | 71,624 | -1% | -$131,285 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale | $207.73 | -526 | 43,294 | -1% | -$109,266 | ||||||
2026-03-02 | DGX | Quest Diagnostics Inc | Davis J. E. | CEO, Pres | S - Sale | $212.52 | -10,000 | 117,185 | -8% | -$2,125,200 | ||||||
2026-03-03 | DGX | Quest Diagnostics Inc | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $207.73 | -410 | 15,198 | -3% | -$85,169 | ||||||
2026-03-02 | VCYT | Veracyte, Inc. | Febbo Phillip G. | Chief Scientific, Med Officer | S - Sale | $36.16 | -13,425 | 117,346 | -10% | -$485,429 | ||||||
2026-03-03 | XGN | Exagen Inc. | Aballi John | Pres, CEO | S - Sale | $3.62 | -15,698 | 730,235 | -2% | -$56,827 | ||||||
2026-03-02 | GRAL | Grail, Inc. | Ofman Joshua J. | Pres | S - Sale | $50.16 | -17,002 | 436,508 | -4% | -$852,848 | ||||||
2026-03-02 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $200.23 | -3,070 | 305,758 | -1% | -$614,710 | ||||||
2026-03-02 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $200.02 | -3,950 | 156,607 | -2% | -$790,095 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |